Adverse events reported in 2 or more patients during the treatment period
| Event . | Romiplostim (n = 17), number (%) . | Placebo (n = 5), number (%) . |
|---|---|---|
| Headache | 6 (35) | 2 (40) |
| Epistaxis | 6 (35) | 1 (20) |
| Oropharyngeal pain | 4 (24) | 0 (0) |
| Pyrexia | 4 (24) | 0 (0) |
| Contusion | 3 (18) | 1 (20) |
| Abdominal pain upper | 3 (18) | 0 (0) |
| Rash | 3 (18) | 0 (0) |
| Cough | 2 (12) | 2 (40) |
| Vomiting | 2 (12) | 2 (40) |
| Petechiae | 2 (12) | 1 (20) |
| Upper respiratory tract infection | 2 (12) | 1 (20) |
| Nasopharyngitis | 2 (12) | 0 (0) |
| Abdominal pain | 1 (6) | 1 (20) |
| Back pain | 1 (6) | 1 (20) |
| Pain in extremity | 1 (6) | 1 (20) |
| Nasal congestion | 0 (0) | 2 (40) |
| Event . | Romiplostim (n = 17), number (%) . | Placebo (n = 5), number (%) . |
|---|---|---|
| Headache | 6 (35) | 2 (40) |
| Epistaxis | 6 (35) | 1 (20) |
| Oropharyngeal pain | 4 (24) | 0 (0) |
| Pyrexia | 4 (24) | 0 (0) |
| Contusion | 3 (18) | 1 (20) |
| Abdominal pain upper | 3 (18) | 0 (0) |
| Rash | 3 (18) | 0 (0) |
| Cough | 2 (12) | 2 (40) |
| Vomiting | 2 (12) | 2 (40) |
| Petechiae | 2 (12) | 1 (20) |
| Upper respiratory tract infection | 2 (12) | 1 (20) |
| Nasopharyngitis | 2 (12) | 0 (0) |
| Abdominal pain | 1 (6) | 1 (20) |
| Back pain | 1 (6) | 1 (20) |
| Pain in extremity | 1 (6) | 1 (20) |
| Nasal congestion | 0 (0) | 2 (40) |